Cooperative Agreement U24CA253539

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $391,703 to The Regents of the University of California, San Francisco (UCSF) to develop rapid, sensitive, and reproducible platforms for screening drugs in a preclinical setting using patient-derived organoids (PDOs). The project aims to improve the uniformity, scalability, and physiological relevance of PDOs to enable more accurate prediction of drug efficacy, with a...

This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $654,197 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on pancreatic cancer patient-derived xenograft (PDX) tumor models. The research aims to: Define the molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) that respond to standard-of-care chemotherapies like FOLFIRINOX and gemcitabine + Abraxane. Elucidate how...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $160,330 to the University of Illinois to develop novel lung adenocarcinoma models that better capture the initiation, progression, and composition of primary human lung tumors. The researchers aim to introduce oncogenic mutations into primary human lung stem and progenitor cells, and then culture them as tumor organoids or xenograft them into immunodeficient mice. This work seeks to...

The National Cancer Institute (NCI) has awarded a $554,653 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Institute for Systems Biology (ISB) in Seattle, WA. The 4-year grant titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES" aims to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs)...

This $388,673 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of novel statistical methods to identify and evaluate predictive biomarkers for targeted cancer therapies using data from non-randomized Phase II clinical trials. The key products of this 2-year project, led by the University of Kentucky Research Foundation, include: Novel semiparametric statistical models to identify and...

This federal Project Grant award, totaling $244,228.00, was provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will fund a research project led by the University of Texas MD Anderson Cancer Center to develop a functional proteomics approach for accurately mapping patient tumor samples to preclinical lung cancer models. The key objectives are to: 1) expand proteomic profiling of lung cancer patient-derived xenograft...

The National Cancer Institute (NCI) awarded a $585,931 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Pittsburgh. The grant, effective February 3, 2025 through January 31, 2030, will support a research project titled "Single-Cell Congruence Evaluation and Selection of Cancer Models Towards Precision Medicine." The project aims to: 1) Identify and clinically annotate prevalent subclones and tumor microenvironment cell types in breast cancer,...

This federal Cooperative Agreement award, funded by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), aims to create a comprehensive 3D atlas depicting the progression of pancreatic cancer precursor lesions to invasive pancreatic ductal adenocarcinoma (PDAC) in individuals with genetic defects in DNA repair genes (BRCA1, BRCA2, PALB2). The $1,035,138 award, with a period of performance from Sep 1, 2024 to Aug 31, 2029, will support...

The National Cancer Institute (NCI) awarded PDX Pharmaceuticals Inc. a $410,652 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance the commercialization readiness of their nanoparticle-based immunotherapy, ARAC-02, for the treatment of non-small cell lung cancer (NSCLC). The funding supports two key activities: 1) Pursuing international patent protection for the company's PDX-NP nanoparticle platform and ARAC-02 compositions, and 2) Initiating...

This $627,833 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) aims to develop an informatics platform that integrates molecular and pathological data from various lung cancer preclinical models and patient tumors. The goal is to assess the fidelity of these preclinical models through comparative analyses. The University of Texas Southwestern Medical Center, the prime awardee, will work with Duke University as a sub-awardee to...